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Abstract 
Treatment of inflammatory disorders with glucocorticoids (GCs) is often accompanied by severe adverse effects. 
Application of GCs via nanoparticles (NPs), especially those using simple formulations, could possibly improve their 
delivery to sites of inflammation and therefore their efficacy, minimising the required dose and thus reducing side 
effects. Here, we present the evaluation of NPs composed of GC betamethasone phosphate (BMP) and the 
fluorescent dye DY-647 (BMP-IOH-NPs) for improved treatment of inflammation with simultaneous in vivo 
monitoring of NP delivery.  
Methods: BMP-IOH-NP uptake by MH-S macrophages was analysed by fluorescence and electron microscopy. 
Lipopolysaccharide (LPS)-stimulated cells were treated for 48 h with BMP-IOH-NPs (1×10-5-1×10-9 M), BMP or 
dexamethasone (Dexa). Drug efficacy was assessed by measurement of interleukin 6. Mice with Zymosan-A-induced 
paw inflammation were intraperitoneally treated with BMP-IOH-NPs (10 mg/kg) and mice with ovalbumin 
(OVA)-induced allergic airway inflammation (AAI) were treated intranasally with BMP-IOH-NPs, BMP or Dexa (each 
2.5 mg/kg). Efficacy was assessed in vivo by paw volume measurements with µCT and ex vivo by measurement of paw 
weight for Zymosan-A-treated mice, or in the AAI model by in vivo x-ray-based lung function assessment and by cell 
counts in the bronchoalveolar lavage (BAL) fluid and histology. Delivery of BMP-IOH-NPs to the lungs of AAI mice 
was monitored by in vivo optical imaging and by fluorescence microscopy. 
Results: Uptake of BMP-IOH-NPs by MH-S cells was observed during the first 10 min of incubation, with the NP load 
increasing over time. The anti-inflammatory effect of BMP-IOH-NPs in vitro was dose dependent and higher than that 
of Dexa or free BMP, confirming efficient release of the drug. In vivo, Zymosan-A-induced paw inflammation was 
significantly reduced in mice treated with BMP-IOH-NPs. AAI mice that received BMP-IOH-NPs or Dexa but not 
BMP revealed significantly decreased eosinophil numbers in BALs and reduced immune cell infiltration in lungs. 
Correspondingly, lung function parameters, which were strongly affected in non-treated AAI mice, were unaffected in 
AAI mice treated with BMP-IOH-NPs and resembled those of healthy animals. Accumulation of BMP-IOH-NPs within 
the lungs of AAI mice was detectable by optical imaging for at least 4 h in vivo, where they were preferentially taken up 
by peribronchial and alveolar M2 macrophages.  
Conclusion: Our results show that BMP-IOH-NPs can effectively be applied in therapy of inflammatory diseases with 
at least equal efficacy as the gold standard Dexa, while their delivery can be simultaneously tracked in vivo by 
fluorescence imaging. BMP-IOH-NPs thus have the potential to reach clinical applications. 
Key words: hybrid nanoparticles, nanoparticle-based therapy, inflammatory disease, monitoring glucocorticoid 
delivery, in vivo imaging  
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Introduction 
Inflammation is a primary defence mechanism 
against infection or injury, is required and beneficial, 
and is strictly coordinated by a wide range of 
mediators. If dysregulated, inflammation can turn 
into a chronic disease and can lead to tissue damage 
or even death. Inflammatory disorders such as 
autoimmune diseases, eczema, allergic asthma or 
food allergies are especially on the rise in the Western 
world [1]. One such inflammatory disorder, allergic 
asthma, is a chronic pulmonary disease characterised 
by a major influx of eosinophils into the lungs, 
degranulation of mast cells, an increased number of 
activated T-cells, mucus hypersecretion, airway 
obstruction and airway hyper-responsiveness. These 
events are orchestrated by a complex network of 
inflammatory mediators including chemokines, 
cytokines and growth factors [2].  
Glucocorticoids (GCs) such as betamethasone or 
dexamethasone are routinely used as an effective 
anti-inflammatory therapy for chronic inflammatory 
diseases such as asthma because they are immune-
suppressive and so inhibit many of the initial events 
in the inflammatory response. GCs modulate target 
gene expression by direct binding of the GC/GC 
receptor complex to GC-responsive elements in the 
promoter region of these genes or by interaction of 
this complex with other transcription factors. GCs 
thus inhibit recruitment of inflammatory cells by 
suppressing the production of chemotactic mediators 
and adhesion molecules, and/or they by supressing 
inflammation by activating anti-inflammatory 
proteins [3–5]. Patients with acute severe asthma are 
usually treated systemically with GCs as first-line 
agent, whereas topical (i.e., inhaled) GCs are used for 
long-term management in patients with persistent 
asthma [6]. In particular, the long term use of systemic 
and/or high doses of GCs is associated with multiple 
severe adverse effects such as immunosuppression, 
hypertension, hyperglycemia, hydroelectrolytic disor-
ders, adrenal insufficiency, weight gain, increased 
skin fragility, myopathy, osteoporosis, metabolic 
disturbances and mood changes [7].  
Obviously, effective treatment of a disease 
depends on efficient and specific delivery of the 
therapeutic agent to the site of action. It has been 
previously shown that this can be improved by using 
nanocarriers such as nanoparticles (NPs), micelles or 
liposomes, which can, e.g., increase the solubility of 
otherwise insoluble drugs, enhance their bioavailab-
ility, extend circulation times, achieve accumulation at 
pathological sites or even allow drug delivery at 
controlled rates [8–10]. In recent years, this has led to 
the development of a number of NPs that have been 
successfully introduced into clinical routine. Among 
them, nanoformulations with improved delivery of 
chemotherapeutics such as Doxil (PEGylated 
liposomal doxorubicin), Abraxane (nab-paclitaxel: 
nanoparticle albumin-bound paclitaxel) or the recently 
approved ONIVYDE (PEGylated liposomal irinote-
can) [11,12] are significant drivers of the development 
of nanomedicine. NPs are also increasingly applied in 
connection with different diseases, e.g., in the 
treatment of fungal infections with AmBisome 
(liposomal Amphotericin B) [13] or as magnetic 
resonance imaging (MRI) contrast agents (iron-oxide 
NPs, such as Sienna+ or Ferumoxytol) [14]. Most of 
these substances are simple formulations based on 
clinically approved building blocks, which aim to 
improve the delivery, specificity and pharmacodyn-
amics of already available therapeutics.  
In this context, improved delivery of GCs to 
inflammatory sites in the lung using GC-containing 
nanoformulations could provide a rapid response, 
minimise the required dose by increasing the local 
drug concentration and decrease systemic side effects 
[15]. GC-based nanotherapeutics, in particular those 
based on liposomal formulations, have recently been 
explored for treatment of various inflammatory 
disorders such as arthritis [16] or multiple sclerosis 
[17] and have been shown to selectively target sites of 
inflammation as well as significantly improve 
treatment efficacy. Various attempts have been made 
to use NPs to improve GC transport to inflammation 
sites in asthmatic lungs [18,19], although none of these 
have reached the clinic yet.  
NPs have the additional advantage that they 
may be combined into hybrid nanomaterials that fulfil 
several functions simultaneously. Such multi-modal 
or multi-functional NPs allow, e.g., for controlled 
drug release together with monitoring of treatment 
delivery. For this purpose, NPs can be loaded with 
multiple fluorescent dyes or used as MRI or CT 
contrast agents [14,20–22]. Recently, we have 
introduced inorganic-organic hybrid NPs (IOH-NPs) 
as a novel group of multifunctional NPs, which can 
easily incorporate versatile functions such as drug 
transport and delivery together with NP tracking 
using fluorescence imaging, MRI or photoacoustic 
imaging (PAI) [22–24]. Our previous in vitro findings 
that fluorescent IOH-NPs containing the GC 
betamethasone phosphate (BMP) are taken up by 
macrophages and efficiently reduce pro-inflammatory 
cytokine TNFα production in stimulated mouse 
macrophages made them attractive for in vivo applic-
ations [23]. We thus postulated that BMP-loaded 
IOH-NPs could act as immunosuppressive drugs for 
the treatment of inflammatory diseases, and we 
analysed them in vivo in a simple model of sterile paw 
inflammation and in a model of allergic airway 
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inflammation (AAI). Our results demonstrate that the 
efficacy of fluorescent BMP-IOH-NPs is significantly 
higher than that of soluble BMP and at least equal to 
that of the gold standard dexamethasone, while their 
delivery can be simultaneously tracked in vivo via 
fluorescence imaging. Interestingly, the NPs were 
specifically localized in alveolar and bronchial M2 
macrophages, suggesting that these cells act as a 
reservoir from which the drugs are released into the 
surrounding tissue.   
Methods 
Preparation and characterisation of IOH-NPs 
IOH-NPs are a saline composition with [ZrO]2+ 
as an inorganic cation and one or more functional 
organic anions resulting in the general composition 
[ZrO]2+[RfunctionOPO3]2−. The [ZrO]2+ cation, which 
guarantees the insolubility of the IOH-NPs in water, is 
highly biocompatible and clinically approved [25,26]. 
The organic anion [RfunctionOPO3]2− has certain 
functionalities such as fluorescence or pharmaceutical 
activity. BMP-IOH-NPs with the chemical compos-
ition [ZrO]2+[(BMP)0.996(DUT)0.004]2− contain the anti- 
inflammatory agent betamethasone phosphate 
([BMP]2−) with an extraordinarily high loading of 81 
wt% as well as a minor amount of the near- 
infrared-emitting dye-modified nucleoside triphos-
phate DY-647-dUTP ([DUT]2−; λEx 653 nm, λEm 672 
nm). The IOH-NPs were prepared by admixing a 
solution of ZrOCl2·8H2O (5 mg, >99%, Sigma-Aldrich, 
Germany) in H2O (2.5 mL) to a solution of sodium 
betamethasone 21-phosphate (Na2(BMP), 50 mg, 
≥97%, Sigma-Aldrich, Germany) in H2O (50 mL) and 
the dye-modified nucleoside triphosphate DY-647- 
dUTP (1.2 mg in 100 µL of H2O, Dyomics, Germany). 
IOH-NPs were then redispersed in dextran 40 
(30 mM, pH = 7.4). The suspension contained 2.1 mg/ 
mL [ZrO]2+[(BMP)0.996(DUT)0.004]2− and 1.7 mg/mL 
BMP. At a pH of 6-8, [ZrO]2+[(BMP)0.996(DUT)0.004]2− is 
highly insoluble in water. Thus, stirring of the NPs 
over 48 h at pH 7 (Hepes buffer) and 37 °C in the 
presence of acid phosphatase results in a BMP release 
of less than 5%. The synthesis, chemical composition, 
particle size, as well as the properties of the [ZrO]2+ 
[(BMP)0.996(DUT)0.004]2− IOH-NPs were described in 
detail before [23]. The presence of the fluorescent dye 
anion [DUT]2− in [ZrO]2+[(BMP)0.996(DUT)0.004]2− was 
validated by fluorescence spectroscopy. For imaging 
of whole mouse cryosections, the fluorescent dye 
indocyanine green (ICG; λEx 788 nm, λEm 813 nm) was 
used instead of DY-647 in order to meet the filter 
settings of the system.  
Scanning electron microscopy (SEM) was carried 
out with a Zeiss Supra 40 VP (Zeiss, Germany) 
equipped with a field emission gun (acceleration 
voltage 1 kV, working distance 3 mm). Samples were 
prepared by placing a droplet of diluted aqueous 
suspension of the sulfonate-based IOH-NPs on a silica 
wafer that was left to dry overnight.  
Dynamic light scattering (DLS) was used to 
determine the hydrodynamic diameter of the BMP- 
IOH-NPs and their size distribution in suspension. 
Studies were conducted in polystyrene cuvettes using 
a Nanosizer ZS (Malvern Instruments, United 
Kingdom).  
Zeta potential measurements were conducted 
using an automatic titrator MPT-2 attached to the 
Nanosizer ZS. For a typical measurement, 1 mL of a 
suspension containing 1 mg/mL of BMP-IOH-NPs 
was diluted with 9 mL of demineralized water. 
Titration was performed using 0.01 M and 0.1 M HCl 
as well as 0.01 M and 0.1 M NaOH. 
Cells and cell culture 
The immortalized and adherent mouse alveolar 
macrophage cell line MH-S (CRL-2019, ATCC) was 
cultivated at 37 °C in a humidified atmosphere of 5% 
CO2 in complete RPMI medium supplemented with 
10% fetal calf serum (FCS) and 0.05 mM 
2-mercaptoethanol. To assess the anti-inflammatory 
potential of BMP-IOH-NPs in vitro, 2×105 MH-S cells 
were plated in 96-well plates in 200 μL medium per 
well and allowed to attach for 24 h. An inflammatory 
response was provoked with 200 ng/mL lipopoly-
saccharide (LPS, Sigma). Simultaneously, the cells 
were either treated with BMP-IOH-NPs or one of the 
control drugs dexamethasone (Dexa; Ratiopharm, 
Germany) or BMP (Sigma-Aldrich, Germany), each at 
concentrations of 1×109 to 1×105 M of active substance. 
After 48 h, the medium was collected and release of 
interleukin 6 (IL-6) into the culture medium was 
measured with the Mouse IL-6 ELISA Kit (Life 
Technologies, Germany), according to the 
manufacturer’s protocol. The absorbance at 450 nm 
was measured with a Wallac 1420 Victor 2 Multilabel 
Counter (Perkin Elmer, Germany). 
For toxicity analysis, MH-S cells were plated on 
96-well plates (10,000 cells per well) and allowed to 
attach. On the following day, the medium was 
replaced with cell culture medium supplemented 
with increasing concentrations (1×109 to 1×105 M) of 
BMP-IOH-NPs, Dexa or BMP, or with corresponding 
volumes of PBS. Cell viability was measured after 
incubation for 2, 24, 48, and 72 h using a CellTiter 96 
Aqueous One Solution Cell Proliferation Assay 
(Promega). The absorbance at 490 nm was measured 
using an Eon microplate spectrophotometer (BioTek). 
For confocal fluorescence microscopy, MH-S 
cells were incubated for different times with 50 
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mg/mL of BMP-IOH-NPs, washed twice with 
phosphate buffered saline (PBS), and then fixed with 
4% paraformaldehyde (PFA) for 10 min at room 
temperature (RT) before being counterstained and 
mounted with ProLong Gold Antifade Mountant with 
DAPI (Thermo Fisher Scientific, Germany). Fluores-
cence was visualized using a SP2 confocal microscope 
(Leica, Germany). 0.25 µm Z-stacks were acquired. 
Electron microscopy 
MH-S cells were incubated with 50 mg/mL of 
BMP-IOH-NPs for various incubation periods and 
fixed with 4% PFA/ 2.5% glutaraldehyde in 0.1 M PBS 
pH 7.3. The cells were then fixed in culture dishes 
with 1% OsO4 (Science Services, Germany) in 0.1 M 
PBS and embedded in Epon (Serva, Germany) after 
dehydration with ethanol and en bloc staining with 
1.5% uranyl acetate (Merck)/ 1.5% tungstophosphoric 
acid (Merck, Germany) in 70% ethanol. Ultrathin 
sections of cultured cells were cut parallel to the 
substrate using an UC7 Ultramicrotome (Leica, 
Germany) and stained with an aqueous solution of 4% 
uranyl acetate followed by lead citrate [27]. Sections 
were analysed with a LEO EM912 Omega (Zeiss, 
Germany) and digital micrographs were obtained 
with an on-axis 2048×2048 CCD camera (TRS). 
Animals 
Pathogen-free female immunocompetent BALB/ 
c mice bred in-house and hairless SKH-1 mice 
(Charles River Laboratories Inc., Germany) were used 
for the Zymosan A-induced paw inflammation model 
and for AAI induction, respectively. Mice were 
housed in a controlled environment at a 12 h dark/ 
light cycle and at 22 °C and were fed laboratory chow 
and tap water ad libitum. All animal experiments were 
performed in accordance with German animal ethics 
regulations and were approved by the local ethics 
office (Niedersächsisches Landesamt für Verbrauche-
rschutz und Lebensmittelsicherheit, LAVES, ethics 
approval no. 33.14-42502-04-13/1185). 
Induction of sterile paw inflammation and 
treatment schedule 
To study the in vivo efficacy of the 
BMP-IOH-NPs, a sterile inflammation was induced at 
day 0 with a transcutaneous/intermuscular injection 
of Zymosan-A (Sigma; 500 µg in 50 µL PBS), an 
insoluble polysaccharide cell wall component of 
Saccharomyces cerevisiae, into the left hind paw of 
BALB/c mice [28]. The contralateral control paw was 
injected with 50 µL of PBS. Two hours later, mice were 
intraperitoneally (i.p.) injected either with BMP-IOH- 
NPs (10 mg/kg body weight (BW); n=7) or with the 
corresponding volume of 0.9% NaCl (n=6) and the 
treatment was repeated on days 1, 2 and 3. Animals 
were sacrificed on day 4 by isoflurane overdose and 
cervical dislocation, and hind paws were isolated at a 
defined position and weighed. 
In vivo micro computed tomography (µCT) 
To quantify the paw volumes, in vivo µCT was 
performed on day 0 before the start of the treatment as 
well as at the end of the study on day 4. Scans were 
carried out under gas anaesthesia (~2% isoflurane in 2 
L/min O2/air mix 50%/50%), with a low-dose in vivo 
µCT (Quantum FX, Perkin Elmer) using the following 
parameters: 70 kVp, 200 μA and a field of view (FOV) 
of 40×40 mm. 3D image visualization and volumetric 
analyses were performed using the 3D analysis 
software Scry v6.0 (Kuchel & Sautter). For volume 
calculation, paws were virtually isolated from the 
centre point between the distal end of the tibia and the 
junction between tibia and fibula and the total volume 
was calculated using a simple threshold-based 
method to separate the surrounding air from the 
tissue. 
Induction of AAI and treatment schedule  
On days 0 and 14, mice were immunized by i.p. 
injection with 50 μg of ovalbumin (OVA, Hyglos, 
Germany) and 0.5% aluminium hydroxide gel 
adjuvant (Invivogen, Germany) in a volume of 0.2 mL 
of PBS, as well as intranasally (i.n.) with 50 μg of OVA 
in 25 μL of PBS. On days 28 and 29, mice were 
challenged i.n. with 250 μg of OVA in 25 μL of PBS to 
induce an acute reaction. For control mice, OVA was 
replaced with PBS in the immunisation steps on days 
0 and 14.  
Mice were treated i.n. with BMP-IOH-NPs, BMP 
or Dexa, each at 2.4 mg of active substance per kg BW. 
The substances were diluted in 0.9% NaCl and 1.43 
µL/g BW was applied. Control animals received 
corresponding volumes of 0.9% NaCl. Treatment was 
given on days 28 and 29, each 30 min before the 
challenge, as well as on day 30. The ICG-containing 
BMP-IOH-NPs (2.4 mg BMP/kg BW) as well as the 
free DY-647 dye (13.97 µg/kg BW; corresponds to the 
amount of dye in BMP-IOH-NPs) were applied using 
the same schedule. All i.n. applications were 
performed under short 2% isoflurane, 2 L/min O2 
anaesthesia. Mice were sacrificed on day 31 by 
isoflurane overdose and cervical dislocation and the 
lungs were either cannulated and lavaged or were 
directly explanted, filled with 600 μL of Tissue-Tek 
OCT compound (Sakura Finetek, The Netherlands), 
and frozen in liquid nitrogen. 
In vivo fluorescence reflectance imaging 
BMP-IOH-NPs fluorescence was measured with 
the Optix MX2 system (ART, Canada) using an 
excitation laser diode of 635 nm in combination with a 
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670 nm band-pass emission filter with 40 nm 
bandwidth. Scans of the lung area were performed 
with a 1.0 mm raster, a photon collection time 
(integration time) of 1 s per scan point, and varying 
laser power. During in vivo scans, mice were 
anaesthetized by inhalation with 2% isoflurane in 2 
L/min O2 for 15-30 min per scan. Pre-treatment scans 
were acquired to assess autofluorescence of the 
animals. Optix 2.02.01 and OptiView 2.01.00 software 
(ART) were used to acquire and analyse the data, 
respectively. Fluorescence intensity data were 
displayed in arbitrary units (normalized counts; NC), 
where the measured fluorescence intensities (counts) 
were normalized for varying laser power and 
integration times, allowing for comparison of 
measurements with different settings. Fluorescence 
lifetime was assessed as previously described [29]. 
In vivo assessment of lung function 
Low-dose x-ray-based in vivo lung function 
measurement (XLF) was performed as previously 
described by Dullin et al. [30]. Briefly, mice were 
anaesthetised with isoflurane and the anaesthesia was 
adjusted to keep the breathing rate to approximately 
1.4 s per breathing cycle. Cinematic x-ray images 
(1024 images) were acquired continuously with a rate 
of 30 images per second with a QuantumFX µCT 
(Perkin Elmer) using the following parameters: FOV 
20×20 mm2, x-ray tube voltage 90 kVp and tube 
current 40 μA, resulting in an entrance dose of about 6 
mGy. Data was analysed using the software XLF [30]. 
The dynamic parameter tin[%] represents the relative 
inhalation time, meaning the ratio of inhalation time 
to total length of a breathing event. 
For diaphragm motion analysis, the average and 
the standard deviation (SD) of the changes in 
brightness for each pixel over time was calculated 
from the acquired x-ray movies using FIJI (National 
Institutes of Health, Bethesda, USA) [31]. Thereby, 
moving areas at the interface of dark and bright 
regions between the lungs and soft tissues beneath the 
lung, which we defined as the diaphragm, show very 
high SDs compared to static areas [32]. The average 
height of the area with high SD was measured at six 
independent positions (three per side) and was used 
as a parameter representing the average diaphragm 
movement (sdia).  
Bronchoalveolar lavage (BAL) 
The trachea of the sacrificed mice was exposed 
and cannulated. BALs were performed by washing 
the airways gently three times with 500 μL of 2% 
FCS/PBS each. Volumes were pooled and washed 
once with the same buffer. Recovered cells were 
counted and approximately 3×104 cells were used for 
cytospins utilising a Shandon Cytospin 4 (Thermo 
Fisher Scientific, Germany), and then stained with 
Giemsa (Sigma-Aldrich) for differential cell counting. 
Approximately 400-500 cells were counted and 
classified as macrophages, eosinophils, neutrophils or 
lymphocytes based on staining colour and 
characteristic morphology. 
Histology, immunofluorescence staining and 
fluorescence microscopy 
For histology, paws were fixed with 4% formalin 
in PBS (pH 7.4) overnight, washed with water and 
incubated with 10% EDTA, 3.3% Tris (pH 7.3) at 4 °C 
for 4-12 weeks. The EDTA/Tris solution was exchan-
ged every few days and the progress of decalcification 
was assessed with a cannula. Decalcified paws were 
washed several times with PBS, dehydrated, washed, 
paraffin embedded, sectioned and stained with 
hematoxylin‐eosin (H&E).  
Cytospins from BALs were fixed with 1:1 
acetone/methanol solution and stained with Giemsa 
or immunostained. Frozen lung sections of 5 μm were 
fixed with acetone and stained with H&E in order to 
evaluate the degree of lung-infiltration with mononu-
clear cells, or pre-treated with 0.3 M glycine before 
using avidin-biotin block and Seablock (Thermos 
Scientific) for immunohistochemistry. For the detec-
tion of macrophages, cytospins and lung cryosections 
were stained with rat anti-mouse CD68 antibody 
(clone FA-11, Abcam, 1:300), followed by incubation 
with biotinylated goat anti-rat antibody (BioLegend, 
1:200) and streptavidin-Alexa Fluor 488 (Life Techno-
logies, 1:400). CD11c cell expression was assessed on 
lung sections with Alexa Fluor 488-conjugated 
anti-mouse CD11c (clone N418, BioLegend, 1:200) and 
MHCII expression was evaluated with Alexa Fluor 
488-conjugated rat anti-mouse MHCII antibody (clone 
M5/114.15.2, Biolegend, 1:200). ECF-L was stained 
with a polyclonal goat anti-mouse ECF-L antibody 
(R&D, 1:150), followed by donkey anti-goat Alexa 
Fluor 488 secondary antibody (Abcam, 1:400). 
Eosinophils were identified by staining with rat 
anti-mouse Siglec-F antibody (clone e50-2440; BD 
Pharmingen), followed by goat-anti-rat biotin, and 
detection with avidin Alexa Fluor 488 (Molecular 
Probes). Hamster anti-mouse podoplanin (Santa Cruz 
Biotechnology, 1:200), followed by goat anti-hamster 
Alexa Fluor 488 secondary antibody (Life Techno-
logies, 1:400) and rabbit anti-mouse prosurfactant 
Protein C (proSP-C) antibody (Millipore, 1:2000), 
followed by goat anti-rabbit Alexa Fluor 488 (Life 
Technologies, 1:400) were used to detect pulmonary 
alveolar type I (AT1) and type II (AT2) cells, 
respectively. All sections were co-stained with DAPI 
(4 μg/mL) for visualization of nuclei and mounted 
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with Aqua-Poly/Mount (Polysciences). 
Images were acquired with a confocal SP-2 
microscope (Leica) and processed with FIJI [31]. 
Imaging of whole mouse cryosections  
One AAI mouse treated with ICG-loaded 
BMP-IOH-NPs was sacrificed and tracheotomised. 
The lung was filled with a mixture of Tissue-Tek and 
black ink (8% w/w) and the entire mouse was 
embedded in a mixture of Tissue-Tek and black ink 
(8% w/w) and frozen. Whole-body cryosectioning in 
transversal planes was performed using a Leica CM 
3500 cryostat at 20 μm steps. A custom-made imaging 
system was utilized to image the remaining block of 
the specimen after every section. Three reflectance 
images were acquired at 630/60 nm (red channel), 
535/38 nm (green channel), and 460/50 nm (blue 
channel) for colour imaging as well as one 
fluorescence image at 810/90 nm (ET810/90, Chroma 
Technology) to capture the main part of the emission 
spectrum of the fluorophore. Additional fluorescence 
images were acquired at 790/10 nm, 810/10 nm, 
830/20 nm, and 860/10 nm (Chroma Technology). 
These data were employed to segment the ICG 
emission from tissue autofluorescence and food 
fluorescence by applying phasor analysis [33,34]. The 
filters were placed in a custom-made motorized 
filter-wheel in the lens-camera path. A halogen light 
source (KL2500, Schott) coupled to fibre bundles and 
a motorized filter-wheel (FW102C, Thorlabs) illumi-
nated the specimen. Reflectance images were enabled 
by white-light illumination (i.e., no light source 
filtering), whereas the fluorescence was excited by a 
fibre-coupled near-infrared (NIR 750 nm, 300 mW) 
continuous-wave diode laser (BWF2-750-0, B&W 
Tek). A Leica Z16 Apo Macroscope projected the 
image onto the sensor of an iXon electron-multiplying 
CCD camera (EMCCD, DV8201-BV, Andor Techno-
logy). The FOV was adjusted to cover the full-body 
cutting plane. Cutting and image-acquisition was 
automated. The sectioning and imaging system 
control and triggering software was developed with 
LabView (National Instruments) [35]. Data analysis 
was implemented in MATLAB (Mathworks). 
Statistical analysis 
Statistical analysis was performed with PAST 
[36]. Significant differences of the mean values 
between two groups were analysed by Student’s 
t-test, with a p-value of 0.1 as the margin for statistical 
significance. All diagrams show mean values ± SEM. 
Results 
In vitro characterisation of BMP-IOH-NPs 
The BMP-IOH-NPs applied here have the 
composition [ZrO]2+[(BMP)0.996(DUT)0.004]2− and cont-
ain the anti-inflammatory agent betamethasone 
phosphate ([BMP]2−) as well as the near-infrared- 
emitting dye-modified nucleoside triphosphate DY- 
647-dUTP ([DUT]4−) (Figure 1A, left). The presence of 
the fluorescent dye anion [DUT]2− was confirmed by 
fluorescence spectroscopy (data not shown). Specific 
advantages of the BMP-IOH-NPs include a straight-
forward aqueous synthesis, simple composition and 
an unprecedentedly high drug load of 81 wt% BMP. 
In the presence of phosphatases, BMP is slowly 
released from the IOH-NPs via metabolic activity 
within 1-3 days. Electron microscopy revealed that the 
BMP-IOH-NPs exhibit a mean particle diameter of 31 
± 10 nm (Figure 1A, middle). In water, nanoparticles 
generally show larger hydrodynamic radii due to a 
rigid layer of adsorbed solvent molecules. Based on its 
high polarity and extensive hydrogen bonding 
networks, this rigid solvent layer is largely expanded 
in water resulting in hydrodynamic diameters of 
40-60 nm (Figure 1A, middle). Aqueous suspensions 
exhibit a high colloidal stability, which can be 
ascribed to a negative surface charge as indicated by a 
zeta potential of -40 mV at pH 6 to 8 (Figure 1A, right). 
For a detailed characterization of [ZrO]2+[(BMP)0.996 
(DUT)0.004]2− IOH-NPs, refer to our previously publi-
shed data [23]. 
To investigate the cellular uptake of BMP-IOH- 
NPs, we incubated mouse alveolar MH-S macropha-
ges with the NPs for different periods (10 min to 24 h) 
and analysed the cells with confocal fluorescence and 
electron microscopy. As shown in Figure 1B, 
NP-derived fluorescence was detectable in the cells as 
early as 10 min after incubation and increased over 
time, resulting in a high cell load after 24 h and thus 
demonstrating that BMP-IOH-NPs are effective 
vehicles for glucocorticoid delivery into the cells. This 
was confirmed by electron microscopy, which clearly 
showed that NPs are internalised within the first 10 
min and are localised in large vesicles within the cells 
(Figure 1C). 
To assess the efficacy of BMP-IOH-NPs in vitro, 
MH-S macrophages were stimulated with the 
endotoxin lipopolysaccharide (LPS) and treated for 48 
h with BMP-IOH-NPs or with the reference soluble 
drugs, BMP and Dexa. The inflammatory response of 
the cells was assessed by quantifying IL-6 cytokine 
release into the cell culture medium. As shown in 
Figure 1D, all drugs effectively reduced IL-6 release 
in a concentration-dependent manner. The 
anti-inflammatory response of BMP-IOH-NPs was 
even stronger than that of the reference drugs, 
especially at lower concentrations (1×10-7 and 1×10-8 
M). This confirmed that BMP-IOH-NPs are not only 
effectively internalised by the cells but evidently also 
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released their BMP drug load. This is in agreement 
with our previously published data [23], where we 
have shown that [ZrO]2+[(BMP)0.996(DUT)0.004]2− 
resulted in vitro in a dose-dependent reduction of 
pro-inflammatory cytokine TNFα secretion from 
LPS-stimulated MH-S macrophages. 
 
 
Figure 1. In vitro characterisation of BMP-IOH-NPs. (A) Features of BMP-IOH-NPs. Left: scheme illustrating the chemical composition 
[ZrO]2+[(BMP)0.996(DUT)0.004]2− and aqueous synthesis; middle: electron microscopy image illustrating a particle size of 31 ± 10 nm; right: zeta potential in mV and its 
dependence on pH. (B-C) In vitro uptake of BMP-IOH-NPs by mouse alveolar MH-S macrophages analysed at different times of incubation by (B) confocal 
fluorescence microscopy with orthogonal projections (red: BMP-IOH-NPs, blue: nucleic stain (DAPI); scale bar 20 µm) and by (C) electron microscopy (scale bar 2 
µm). Internalisation is detectable as early as 10 min of incubation and the NP load increased continuously over 24 h (arrows). (D) Efficacy of the BMP-IOH-NP in 
comparison to the control drugs BMP or Dexa (each 1×10-5 – 1×10-9 M of the active substance) on LPS-stimulated MH-S cells assessed by measurement of IL-6 level 
in the cell supernatant after 48 h of treatment. The anti-inflammatory effect of BMP-IOH-NPs on MH-S cells was dose dependent and comparable to that of Dexa and 
BMP, confirming efficient release of the drug from the NPs. Red lines show the mean IL-6 level in the non-treated LPS-stimulated cells. (E) Metabolic activity of MH-S 
murine macrophages after cultivation for 2, 24, 48, and 72 h with BMP-IOH-NPs or with corresponding volumes of PBS. Measurements were performed in triplicates; 
error bars correspond to standard deviation.  
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Despite substantial internalization and strong 
anti-inflammatory activity, BMP-IOH-NPs had no 
effects on the viability and/or metabolic activity of 
MH-S cells, as assessed by cell proliferation assays 
(Figure 1E). Cells treated for up to 72 h with 
increasing amounts of BMP-IOH-NPs showed the 
same behaviour as untreated cells or cells treated with 
corresponding amounts of PBS. Similarly, both Dexa 
and BMP had no negative effects on the viability of 
MH-S cells (data not shown). 
BMP-IOH-NPs effectively reduce sterile paw 
inflammation 
To study the anti-inflammatory efficacy of BMP- 
IOH-NPs in vivo, we first applied them in a sterile 
model of paw inflammation, which allows the simple 
assessment of the anti-inflammatory potential of 
novel drugs. The sterile inflammation was induced by 
a single transcutaneous/intramuscular Zymosan A 
injection into the left paws of BALB/c mice, which led 
to the development of paw oedema, whereas 
contralateral paws injected with the same volume of 
PBS did not show any swelling of the tissue (Figure 
2A-B). Starting at 2 h post Zymosan A injection, mice 
were treated intraperitoneally (i.p.) daily for 4 days 
with BMP-IOH-NPs (10 mg/kg BW of active 
substance), whereas controls received corresponding 
volumes of 0.9% NaCl. Mice treated with BMP-IOH- 
NPs showed no obvious toxic effects, no weight loss 
and an overall good condition (data not shown). 
 
 
Figure 2. Evaluation of the in vivo anti-inflammatory effect of BMP-IOH-NPs in a sterile model of paw inflammation. (A) Macroscopic appearance 
and (B) representative µCT-scan of a non-treated control mouse showing the development of oedema in the Zymosan A-injected but not in the contralateral 
PBS-injected paw. (C) The paw weights determined at the end of the experiment (day 4) showed significantly lower (p=0.015) development of Zymosan A-induced 
paw oedema in BMP-IOH-NPs-treated mice (n=7) than in the control group (n=6). (D) Paw volumes of the same mice measured in vivo by µCT before treatment (day 
0) and at the end of the experiment (day 4) confirmed the significant reduction on paw swelling in the BMP-IOH-NPs-treated mice in comparison to the controls 
(p=0.06). Contralateral PBS-injected paws all had comparable values of weights/volumes and did not show any swelling. Data are presented as mean values; error bars 
represent SEM.      * corresponds to p<0.1 analysed by Student’s t-test (PAST). (E-F) Representative H&E-stained sections of Zymosan A-injected paws from mice 
treated with (E) 0.9% NaCl (controls) and (F) BMP-IOH-NPs. Reduction of immune cells infiltration and the presence of exudate in the intercellular spaces in response 
to BMP-IOH-NPs treatment are shown in higher magnification and are labelled with arrows. Scale bars in the insets of (E-F): 100 µm. 
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As shown in Figure 2C-D, the oedema 
development in Zymosan A-injected paws was clearly 
reduced by BMP-IOH-NPs. At the time of dissection, 
the paws had significantly lower weights (Figure 2C) 
than those from control mice (0.186 ± 0.011 g vs. 0.228 
± 0.007 g; p=0.015). In accordance, mice treated with 
BMP-IOH-NPs also showed clearly reduced volumes 
due to a lesser extent of paw swelling (from 155.9 ± 5 
mm³ at day 0 to 181.1 ± 14.2 mm³ at day 4) in 
comparison to the control group (from 155.9 ± 3.8 
mm³ at day 0 to 222.4 ± 13.6 mm³), although the 
difference was not statistically significant (p=0.06; 
Figure 2D). The contralateral PBS-injected paws did 
not develop any oedema and were not affected by the 
treatment with BMP-IOH-NPs or 0.9% NaCl and at 
the time of the dissection showed almost identical 
weights (0.151 ± 0.002 g vs. 0.162 ± 0.003 g) and 
volumes (149.5 ± 7.5 mm³ vs. 154.3 ± 3.0 mm³). 
Histological analyses showed a dense infiltration 
of mononuclear cells and severe inflammation of soft 
tissue in the Zymosan A-injected paws of control 0.9% 
NaCl-treated mice (Figure 2E). In comparison, the cell 
mass detected at sites of inflammation of the treated 
group was significantly reduced in density and 
exudate was present in the intercellular spaces, 
suggesting a reduction of the inflammatory process in 
response to BMP-IOH-NPs (Figure 2F).  
Effects of BMP-IOH-NPs treatment on the 
inflammatory response of the lung 
We then went on to test the treatment efficacy of 
BMP-IOH-NPs in a mouse model of allergic airway 
inflammation (AAI) using hairless immunocompetent 
SK-H mice, which facilitate the assessment of the 
potential of these NPs for in vivo tracking by 
fluorescence imaging.  
In a series of four independent experiments, AAI 
was induced by using a conventional OVA protocol 
(Figure 3A) [37]. Mice were treated intranasally (i.n.) 
with either BMP-IOH-NPs or with the reference drugs 
Dexa or BMP, each at a concentration of 2.4 mg of 
active substance per kg BW. Control groups of healthy 
and AAI mice were treated i.n. with the same volume 
of PBS. The distribution of BMP-IOH-NPs in the AAI 
lungs was monitored by in vivo epi-fluorescence 
imaging 1 h and 4 h after treatment as well as at the 
end of the experiment, 24 h after the last NP 
application. Here too, the overall condition of the 
treated animals was good, with no weight loss during 
the experiment (data not shown). 
Before application to the animals, we measured 
the average fluorescence lifetime of the BMP-IOH- 
NPs in vitro to be ~1.7 ns (Figure 3B). In vivo 
accumulation of the BMP-IOH-NPs in the lung was 
clearly visible as early as 1 h after instillation and was 
still detectable at 4 h but was usually strongly 
decreased at 24 h (Figure 3C). Additionally, 
accumulation of BMP-IOH-NPs was frequently 
detected in the area of the pharynx/trachea (Figure 
3C) at early time points after injection (1-4 h; Figure 
3C) and most probably resulted from some 
entrapment of NPs in the mucus during i.n. 
instillation. Interestingly, at 1 h post NP instillation, 
along with the NP-derived fluorescence detectable in 
the lung, a slight homogenous increase in background 
fluorescence was measured throughout the entire 
scanned area. This background signal had a 
probe-specific lifetime (~1.6 - 1.7 ns) and was no 
longer observed in scans performed 4 h post 
instillation. At this time point, the BMP-IOH-NP- 
specific lifetime was only detectable over the lung 
area (Figure 3C). As fluorescence lifetime is indepen-
dent of dye/particle concentration, we believe that a 
small part of BMP-IOH-NPs or decomposed 
NPs/fluorescent dye passively or actively reached 
circulation. This would result not only in a slight 
increase in the whole-body fluoresceence intensity, 
but also in a probe-specific lifetime, as measured over 
the entire scanned area 1 h after NP application. 4 h 
and 24 h after NP application, the BMP-IOH-NP- 
derived lifetime was only detectable over the areas 
with a high fluorescence intensity, e.g., the lung, 
suggesting that at later time points no or negligible 
NPs/dye was present in the circulation (Figure 3C). 
In all AAI mice, we observed a significant 
increase in the total number of cells recovered by BAL 
when compared to control mice that received 0.9% 
NaCl (6.33 ± 0.89 ×105 vs. 2.53 ± 0.41 ×105; Figure 4A, 
left). Treatment of AAI mice with BMP-IOH-NPs 
significantly (p=0.03) reduced the total cell number in 
the lavages to 4.09 ± 0.52 ×105. As expected, a similar 
cell count was found in AAI mice treated with the 
control drug Dexa, (4.40 ± 0.84 ×105), although the 
difference was not statistically significant when 
compared to untreated AAI mice (p=0.13). 
Interestingly, treatment of AAI mice with soluble 
BMP did not affect the total cell count in the lavage 
(6.12 ± 1.0 ×105; p=0.87). The effects of the different 
treatments were even more prominent for the 
eosinophil counts in the lung lavage (Figure 4A, 
middle). While BALs from healthy controls contained a 
negligible amount of eosinophils (87 ± 87), induction 
of AAI with OVA resulted, as expected, in a 
significant increase in the total eosinophil numbers 
(2.65 ± 0.86 ×105; p=0.00012). While AAI mice treated 
with BMP-IOH-NPs and with Dexa had significantly 
fewer eosinophils in their BALs than mice from the 
untreated AAI group (0.77 ± 0.29 ×105; p=0.005 and 
0.41 ± 0.16 ×105; p=0.004, respectively), the soluble 
BMP had almost no effect on the AAI-induced 
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eosinophilia, which remained at an average of 2.44 ± 
0.74 ×105 eosinophils (p=0.84). The total number of 
macrophages (Figure 4A, right) in the BAL of AAI 
mice (3.17 ± 0.28 ×105) was slightly higher than that in 
the healthy control mice (2.49 ± 0.41 ×105) and was not 
significantly affected by any treatment, with 3.03 ± 
0.31 ×105, 3.47 ± 0.48 ×105 and 3.23 ± 0.25 ×105 in the 
BMP-IOH-NPs-, Dexa- and BMP-treated mice, 
respectively. While macrophages accounted for 98% ± 
0.3% of total BAL cells in the healthy control mice, 
they accounted for 56% ± 2.5% of total cells in the AAI 
mice.  
The different treatment effects were confirmed 
by histology of lung slices (Figure 4B), which showed 
strong infiltration of the lungs of AAI mice with 
immune cells, which was not detectable in healthy 
controls. This infiltration was strongly reduced in 
mice treated with both BMP-IOH-NPs and Dexa but 
was still present in mice who received soluble BMP. 
 
 
Figure 3. Accumulation of BMP-IOH-NPs in the lungs of AAI mice monitored by epi-fluorescence imaging in vivo. (A) Immunization and challenge 
scheme for the AAI model and experimental setup for treatment and imaging. (B) In vitro scan of BMP-IOH-NPs stock solution showing fluorescence intensity (upper 
panel) and lifetime (lower panel), as well as a representative photon time of flight histogram (right) used for the automatic calculation of the fluorescence lifetime (1.7 
ns). (C) In vivo scans of the lung area (indicated with the inset on the mouse cartoon) before (0 h), 1 h and 4 h (days 28-30) as well as 24 h (day 31) after i.n. instillation 
of BMP-IOH-NPs. Upper panel: fluorescence intensity in normalised counts (nc); lower panel: lifetime in nanoseconds (ns). High fluorescence intensity was observed 
in the area of the pharynx/trachea (T) and lung (L). A homogeneous distribution of the probe-derived lifetime of ~1.6-1.7 ns was found throughout the scanned area 
at 1 h post instillation. At later time points the specific lifetime was only detectable over the lung area (red arrow). 
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Figure 4. In vivo assesment of the efficacy of BMP-IOH-NPs in the AAI mouse model. (A) Total cell counts (left), eosinophils (middle) and macrophages 
(right) recovered by BAL from AAI SKH-1 mice treated with PBS (AAI), BMP-IOH-NPs (AAI/BMP-IOH-NPs), soluble BMP (AAI/BMP) or Dexamethasone 
(AAI/Dexa) as well as from healthy controls. (B) Corresponding H&E staining showing that BMP-IOH-NPs and Dexa, but not BMP, strongly reduced the degree of 
cell infiltration around blood vessels and bronchi in AAI mice to levels comparable to those of controls. Scale bars: 100 µm. (C) XLF-based in vivo analysis of the 
relative inspiration time upon different treatments. (D) Diaphragm motion analysis. Left: representative images showing the SD of x-ray attenuation over time during 
breathing in a AAI and a control mouse. The white colour corresponds to a high SD, representing moving areas over time. Yellow arrows mark the motion amplitude 
of the lung-diaphragm interface. Right: analysis of the diaphragm motion upon different treatments. (A, C-D) Data are presented as mean values; error bars represent 
SEM. Significance was analysed in comparison to AAI mice. * corresponds to p<0.1. 
 
Alterations in lung function were assessed in vivo 
by x-ray-based lung function (XLF) analysis [30,32], a 
method based on parameterization of the average 
x-ray transmission in the chest region using low-dose 
planar cinematic radiography. We investigated two 
selected XLF parameters: the relative inspiration time, 
and the movement of the diaphragm. As shown in 
Figure 4C, the relative inspiration time, which depicts 
the ratio of inspiration time to average length of the 
breathing cycle (tin[%]), was strongly and significantly 
reduced in AAI mice when compared to healthy 
controls. This reduction was not obtained in AAI mice 
treated with any of the three treatments, although for 
mice treated with BMP-IOH-NPs and Dexa the 
difference to untreated AAI mice was significant. Our 
observations from the diaphragm motion analysis 
were consistent with these results. As shown in 
Figure 4D, the extent of diaphragm movement was 
strongly and significantly increased in AAI mice 
compared to healthy controls, suggesting an effect on 
the elasticity of the lung as previously reported [32]. 
This increase was not observed upon treatment of 
AAI mice with BMP-IOH-NPs and Dexa, confirming 
the potent anti-inflammatory efficacy of the 
treatments. However, soluble BMP did not prevent 
the altered movement of the diaphragm observed in 
AAI mice.  
We also analysed other XLF parameters that do 
not reflect the dynamic properties of the lung 
movement during the breathing cycle but that directly 
relate to x-ray transmission. In x-ray images, the lungs 
of mice treated with BMP-IOH-NPs were generally 
darker than those of all other treatment groups and 
controls, suggesting that x-ray transmission is affected 
by the presence of zirconium and cannot be reliably 
quantified (data not shown). 
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Figure 5. Uptake of BMP-IOH-NPs in the lungs of AAI mice. (A) From left to right: Isosurface reconstructed from the sliced part of the mouse. Maximum 
intensity projection (MIP) at the logarithmic scale of the fluorescence recorded at 810/90 nm. The same MIP with the specific ICG fluorescence (orange) segmented 
from phasor analysis. (B) Representative transverse whole-mouse cryosections obtained at the three planes indicated by the red lines on the cartoon (left). 
Morphology (morph.) and fluorescence scans (fluoresc.; green) of the same slice, as well as their overlays (merged) are shown. The fluorescence is predominantly 
localised in the lung (yellow line drawing) and trachea (T; yellow line drawing). Note that the signal detected at the trachea equals ~4% of the fluorescence emitted 
from the lungs. (C-D) Anti-CD68 staining (green) of (C) cytospins from BALs and (D) whole-lung cryosections demonstrate uptake of BMP-IOH-NPs (red) by 
CD68+ cells, especially in the alveolar and bronchial areas (arrows). Note that BMP-IOH-NPs-positive cells were never found in dense areas of infiltrated immune 
cells, including the macrophages (asterisk). Nuclei are stained with DAPI (blue). Bottom panels show magnifications of the selected areas in the top panels. MØ = 
macrophages; eos = eosinophils. Scale bars in (C-D) represent 100 µm in upper panels and 20 µm in lower panels. 
 
BMP-IOH-NPs are prefentially taken up by 
bronchial and alveolar macrophages 
In order to assess the localisation of BMP-IOH- 
NPs in the lungs, a BMP-IOH-NPs-treated AAI mouse 
was directly frozen without prior BAL. The whole 
mouse was then cryosliced and the distribution of 
fluorescence on each cryoslice was analysed in 
relation to the mouse anatomy. As shown in Figure 
5A-B, the NP-derived fluorescence was, as expected, 
predominantly detected in the lung tissue, while no 
fluorescence was present in the liver or kidneys. 
Although we detected some fluorescence signals in 
the trachea, more cryo-imaging experiments are 
required to validate their source. Spectral unmixing of 
the data shown in Figure 5A could not attribute this 
signal to ICG. Additional experiments will validate 
whether this signal is due to autofluorescence or ICG. 
To identify the cells that take up BMP-IOH-NPs, 
we immunostained cytospins from BALs as well as 
frozen lung tissue sections with dye-labeled 
anti-CD68 antibody, a widely used pan-macrophage 
marker. As shown in Figure 5C, in cytospins from 
BALs of BMP-IOH-NPs-treated AAI mice, the NPs 
were cleary localised in CD68+ cells and were not 
taken up by any other cells such as eosinophils, which 
were easily distinguished by their fragmented or 
donut-shaped nucleus. Similar results were observed 
on the whole lung cryosections (Figure 5D), where the 
BMP-IOH-NPs were clearly located within CD68+ 
inflammatory cells in alveolar spaces and in the 
bronchial lumen. Interestingly, we never found NPs 
in CD68+ cells located in the cell mass around bronchi 
and vessels, which we defined as interstitial 
macrophages (Figure 5D, asterix). 
BMP-IOH-NPs were also applied i.n. to control 
mice, where they were similarly taken up by CD68+ 
phagocytic cells (data not shown). Furthermore, we 
also i.n. applied the free fluorescent dye Dy-647 to 
AAI and control mice. Neither in vivo epi-fluorescence 
imaging nor microscopy showed any accumulation or 
uptake of free dye in the lungs of these mice (data not 
shown). 
To analyse the cells that internalise BMP-IOH- 
NPs in AAI mice in more detail, we performed 
immunohistochemistry of whole lung cryosections 
with antibodies to the following protein panel: i) 
CD11c, which is expressed at high levels on most 
dendritic cells, but also on monocytes, macrophages 
and neutrophils; ii) ECF-L (eosinophil chemotactic 
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factor-L), a lectin primarily expressed on M2 macro-
phages; iii) MHCII, which is predominantly expressed 
on M1 macrophages; iv) SiglecF, an eosinophil 
marker; v) proSP-C, a marker for AT2 and vi) podo-
planin, a marker for AT1 cells. As shown in Figure 6, 
the BMP-IOH-NPs were predominantly internalised 
by CD11c+, ECFL+, MHCIIlow, SiglecF−, proSP-Clow, 
and podoplanin− cells, which can be identified as 
peribronchial and alveolar M2 macrophages, as well 
as by a small number of proSP-C+ AT2 cells. 
Discussion 
Glucocorticoids (GC) are traditionally the drug 
of choice for treatment of the vast majority of immune 
disorders. However, along with their benefits come a 
number of side effects and their delivery to the site of 
inflammation is often difficult to predict, especially 
upon systemic application. Here, we demonstrate that 
GCs such as BMP can be applied as fluorescent 
inorganic-organic hybrid nanoparticles to improve 
the treatment efficacy of inflammatory diseases and to 
allow simultaneous tracking of BMP-IOH-NPs 
delivery by in vivo epi-fluorescence imaging and 
microscopy. BMP-IOH-NPs are especially 
advantageous because  they show a low material 
complexity and are prepared by straightforward 
forced hydrolysis in water, while at the same time 
providing a high drug loading of up to 80 wt% [23]. 
The potential use of clinically approved constituents, 
such as BMP or ICG applied here, together with the 
simple preparation of the NPs as an insoluble saline 
compound in water would advance their translation 
into the clinic. 
 
 
Figure 6. Analysis of BMP-IOH-NP uptake in AAI lungs. Lung cryoslices were stained with antibodies targeting (A) CD11c, (B) ECF-L, (C) MHC II, (D) 
SiglecF, (E) proSP-C and (F) podoplanin (each in green). Cells that internalised BMP-IOH-NPs (red; arrows) were identified as CD11c+, ECFL+, MHC IIlow, SiglecF− 
peribronchial and alveolar M2 macrophages as well as a few proSP-C+ AT2 cells. Nuclei are stained with DAPI (blue). Bottom panels show magnifications of the 
selected areas in the top panels. Scale bars represent 100 µm in upper panels and 20 µm in lower panels. 
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In our experiments, BMP-IOH-NPs resulted in 
improved therapeutic efficacy both in vitro and in vivo 
when compared to free BMP. In vitro, this effect was 
especially prominent at concentrations of the active 
compound between 10-7 and 10-8 M, at which 
BMP-IOH-NPs reduced IL-6 production in 
LPS-stimulated MH-S cells even more than both free 
control drugs, Dexa and BMP. In mice with sterile 
paw inflammation, we observed a clear decrease in 
paw swelling upon intraperitoneal treatment of the 
mice with BMP-IOH-NPs, with excellent tolerance in 
the treated animals. Matching results were obtained 
ex vivo by both paw weight measurement and CT 
imaging, which revealed reduced paw weights and 
volumes, respectively, in the BMP-IOH-NPs-treated 
mice, confirming their high efficacy for treatment of 
inflammation.  
In the model of OVA-induced AAI using both 
traditional methods such as BAL cell count and 
histology as well as in vivo x-ray-based lung function 
measurements, we showed that i.n.-instilled BMP- 
IOH-NPs i) efficiently reduced AAI symptoms, like 
infiltration of eosinophils into the lung tissue, to levels 
comparable with that of Dexa-treated mice and 
healthy controls, and ii) clearly exhibited a higher 
efficacy than soluble BMP applied at the same dose. 
Consistently, XLF parameters “relative inspiration 
time” tin and diaphragm motion revealed that only 
mice treated with BMP-IOH-NPs or Dexa, but not 
those treated with soluble BMP, showed an 
anti-inflammatory effect with values similar to those 
of healthy controls. Tin represents the ratio of time of 
inspiration to the duration of the whole breathing 
sequence and is normally decreased in AAI mice due 
to the longer exhalation period caused by the reduced 
elastic recoil of the lung tissue in these animals [32]. In 
healthy animals, inspiration involves active contrac-
tion of the diaphragm and the intercostal muscles 
while exhalation occurs more passively and depends 
on the elastic recoil of the lung. When the latter is lost, 
AAI mice need to put much more effort into pushing 
the air out of the lung, which leads to longer 
exhalation (and shorter relative inspiration) times as 
well as stronger movement of the diaphragm [30,32]. 
This is in agreement with our observations that 
vehicle-treated AAI mice whose lungs are infiltrated 
by a high number of immune cells showed dramatic-
ally reduced parameter tin, which was improved upon 
treatment with BMP-IOH-NPs and Dexa and to a 
lesser extent with soluble BMP. In accordance with 
our previous observations [32], we also showed that 
the diaphragm movement calculated from the x-ray 
movies was aberrantly strong in AAI mice. In mice 
treated with BMP-IOH-NPs or Dexa, but not with 
soluble BMP, this aberrant movement was reduced to 
a level resembling that of healthy controls. These 
results are highly consistent with all other data 
obtained in this study and confirm the high efficacy of 
BMP-IOH-NPs for treatment of inflammation. 
The XLF parameters assessed in our study—the 
relative inspiration time tin and diaphragm motion— 
are both “dynamic” parameters that reflect the 
kinetics of the lung movement during the breathing 
cycle. In evaluations of the lung “transparency” over a 
breathing cycle, we previously showed that AAI mice 
also demonstrate changes in other XLF parameters 
that reflect differences in air content due to thickening 
of the lung tissue [30]. Interestingly, in our 
experiments, these parameters seem to be affected by 
the presence of zirconium, because BMP-IOH-NPs 
influenced x-ray transmission in the lung region and 
resulted in overall darker x-ray images of 
BMP-IOH-NPS-treated lungs compared to untreated 
lungs (data not shown). It is thus possible that 
treatment with BMP-IOH-NPs impacted other XLF 
parameters too, which, however, could not be 
recognized (or quantified) due to the overall increased 
x-ray absorbance caused by the NPs. At the same 
time, this observation suggests that BMP-IOH-NP- 
loaded macrophages could potentially also be 
visualised by high-resolution x-ray technologies, or 
used for x-ray-based virtual histology, as previously 
described for barium-loaded NPs [38]. Such an 
approach would allow 3D analysis of the homing sites 
of loaded macrophages in respect to local anatomical 
alterations.  
Our XLF data as well as paw volume 
measurements by CT delivered valuable parameters 
to assess GC efficacy and thus notably showed the 
advantages of using imaging modalities for 
monitoring the progression of inflammatory disease. 
In particular, non-invasive low-dose CT facilitates 
longitudinal assessment of the course and extent of 
inflammation. While MRI could potentially be used to 
monitor progression of inflammation, this imaging 
modality requires long scanning times and complex 
infrastructure and delivers a much lower resolution in 
comparison to x-ray-based technologies.  
The route of administration undoubtedly affects 
the biodistribution and thus possibly also the efficacy 
of therapeutic compounds. In our experiments 
performed in the paw inflammation model, we chose 
an i.p. application since it is less burdensome to the 
animals than intravenous (i.v.) application, especially 
upon repetitive administration (here on three 
consecutive days). I.v. application could possibly 
generate divergent results, since it is well known that 
i.v.-applied particles are usually rapidly taken up by 
the mononuclear phagocyte system (MPS) and 
accumulate in the liver. This often reduces their time 
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of circulation and lowers their accumulation at the 
desired sites [39]. Furthermore, in our previous 
studies, we i.v.-applied analogous IOH-NP with the 
composition [GdO]+[ICG]- and observed their 
accumulation in the liver within ~5 h after injection 
[22]. Whether this would be the case for 
BMP-IOH-NPs and to what extent it would affect 
their therapeutic effects remains to be analysed.  
In this context, the unique trait of the BMP-IOH- 
NPs presented here is their simple composition that 
incorporates fluorescent dye molecules (Dy-647 or 
ICG) together with the therapeutic compound, 
allowing for simultaneous monitoring of their 
biodistribution and drug delivery. This was well 
demonstrated in the AAI model, for which we used 
hairless SKH-1 mice to minimize loss of fluorescence 
signals. Our longitudinal in vivo fluorescence imaging 
experiments demonstrate that the NPs are quickly 
and efficiently delivered to the lung, where they 
accumulate for at least 24 h, which apparently was a 
sufficient period for the drug to take effect. This 
information is especially important as deposition of 
inhaled drugs and in particular of NPs in the lung is 
difficult to predict as it depends on a variety of factors 
such as particle size, composition, shape or charge, 
but also on breathing rate or structural properties of 
the lung [40]. The advantage of the incorporated 
fluorescent compound was particularly apparent by 
additionally revealing a “loss” of some NPs in the 
pharynx and oesophagus. Because mucus 
over-production is a symptom of asthma, we assume 
that these signals were caused by part of the NPs 
sticking to the mucus in the upper airways and being 
continually swallowed and excreted. Not only does 
this demonstrate the advantage of monitoring 
biodistribution, it also confirms the high potency of 
the BMP-IOH-NPs despite this apparent loss of NPs. 
An alternative application route that may prevent loss 
of NPs in the mucus could be by intratracheal 
instillation. However, this method is much more 
invasive than intranasal delivery, requires long 
anaesthesia times and usually leads to irritation and 
sometimes even inflammation of the airways. It was 
therefore not used for BMP-IOH-NPs application. 
The fluorescence lifetime measurements 
performed in our study offer an additional advantage 
to unravel the biodistribution of the probe by showing 
that, especially at early time points after application, 
low concentrations of the probe are present in the 
entire body or at least the scanned area (upper 
thorax). Because fluorescence lifetime is independent 
of dye/particle concentration, we believe that at early 
time points post instillation there is a minor portion of 
either the intact NPs or the released fluorescent dye 
present in the circulation with blood clearance times 
below 4 h. 
We showed that i.n.-applied BMP-IOH-NPs, 
with an average size of about 30 nm, are taken up by 
peribronchial and alveolar macrophages. Our exten-
sive staining protocol identified these macrophages as 
M2 macrophages. In vitro, using the MH-S cell line, we 
found that the internalisation process occurs very fast 
and could be detected as early as 10 min after 
incubation. Electron microscopy showed a typical 
internalisation pathway, with the particles ending up 
in large vesicles, which is known from other NPs [41]. 
Similar uptake of intranasally applied 100 nm 
polystyrene NPs by the bronchial and alveolar 
macrophages was already observed in our previous 
studies [37]. 
Recently, it has been shown that alveolar type 2 
(AT2) cells, rather than immune cells, seem to be 
major players in the response of AAI lungs to GCs 
[42]. This is especially interesting because, despite the 
minimal uptake by AT2 cells, we observed a high 
treatment efficacy of BMP-IOH NPs, suggesting that 
macrophages that take up BMP-IOH-NPs must also 
play a significant role in the transfer of GC efficacy in 
AAI and probably in general in the treatment of 
inflammation. Similar BMP-IOH-NPs were recently 
applied in a mouse model of multiple sclerosis and 
compared to free GC showed an increased specificity 
for phagocytic cells but not for T cells or brain 
endothelial cells, while retaining full therapeutic 
efficacy [17]. One explanation for the high efficacy of 
BMP-IOH-NPs could be that macrophages, which 
internalise the NPs, act as a depot, slowly releasing 
the drug to the environment and allowing it to act on 
receiver-cells, such as AT2 cells or eosinophils. A 
similar phenomenon has already been described in 
the context of tumour therapy by the group of 
Weissleder, who showed that therapeutic fluorescent 
NPs promote long drug circulation and alter 
accumulation by directing cellular uptake toward 
tumour-associated macrophages (TAMs). TAMs were 
suggested to serve as a local drug depot that 
accumulates significant vehicle from which the drug 
payload gradually releases to neighbouring tumour 
cells [43]. These findings support the notion that 
encapsulation of the drug in NPs, such as 
BMP-IOH-NPs, that can then be easily taken up by 
macrophages can improve therapeutic efficacy.  
One of the most important benefits of IOH-NPs 
is their simple formulation based on the inorganic 
cation [ZrO]2+ used in this study and organic anion(s), 
here the combination of [DUT]2- and [BMP]2-, together 
with simple synthesis by precipitation in aqueous 
solution [23]. Each component can be easily replaced 
to modify the particle function and field of applica-
tion. In our previous studies, we have already shown 
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that IOH-NPs with the composition [GdO]+[ICG]- can 
be efficiently detected by MRI. The replacement of 
[ZrO]2+ with [GdO]+ could thus create an anti- 
inflammatory probe that can be tracked by MRI in 
addition to fluorescence imaging. This is especially 
interesting as the application of fluorescence imaging 
in patients is very restricted due to the limited 
penetration depth. A hybrid probe for fluorescence 
and MR imaging could therefore be used in both 
preclinical and clinical approaches for a comprehend-
sive understanding of the biodistribution of the drug.  
Analogously, the organic compound of IOH-NPs 
can also be exchanged with other organic anion(s), as 
has been already shown, e.g., for [ZrO]2+[FdUMP]2-, 
which contains an active cytostatic agent instead of 
anti-inflammatory BMP [23]. At the same time, 
IOH-NPs offer the possibility of integrating several 
organic compounds in the same particle, such as the 
fluorescent dyes [DUT]2- or [ICG]2- used here together 
with the inflammatory agent [BMP]2-.  Similarly, 
different drugs can also be incorporated in one 
particle, which could potentially increase their 
efficacy and field of action. 
To move toward the goal of clinical translation of 
IOH-NPs as potential macrophage-mediated drug 
delivery systems, in particular of BMP-IOH-NPs for 
the treatment of inflammation, it is still necessary to 
evaluate their exact underlying mechanisms as well as 
their drug release profiles, especially in in vivo 
settings.  
Conclusions 
We show that glucocorticoids such as BMP 
applied in the form of fluorescent IOH-NPs allow 
more efficient treatment of inflammatory disease than 
the equivalent free drug and provide simultaneous 
non-invasive monitoring of NP delivery by optical 
imaging. 
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